Shares surged 12.5% to $13.69 in pre-market trading Thursday as investors continued to reprice Korro Bio around a string of Wall Street upgrades that have dramatically reshaped sentiment on this small RNA-editing drugmaker since January.

Six Firms Flipped Bullish in Five Months — That's Unusual for a $200 Million Company

Piper Sandler upgraded Korro to Overweight with a $30 price target, up from $11.

Oppenheimer set a $22 target.

Raymond James moved to Outperform at $23.

Jones Trading upgraded to Buy, also at $23.

Citigroup initiated coverage with a Buy rating and a $21 target. For a company with a market cap of roughly $199 million , this wall of bullish calls is outsized — and it is the primary engine behind the stock nearly tripling from its 52-week low of $5.20.

The Bet Is on a Drug That Hasn't Entered Human Trials Yet

Korro plans to file for clinical trials of its lead therapy for hyperammonemia — a dangerous buildup of ammonia in the blood — in the second half of 2026.

Raymond James says early data "give line of sight" to proof-of-concept in conditions with "very high unmet need and no approved therapies." That is promising but extremely early. Analysts still project the company will lose $5.36 per share this year with only $4.8 million in trailing-twelve-month revenue.

An $85 Million Cash Raise Buys Time, Not Certainty

A recent oversubscribed $85 million private placement extends Korro's cash runway to the second half of 2028. That gives management enough funding to reach key data readouts without needing to raise more money soon — a critical comfort for shareholders of a company burning cash fast. Korro holds more cash than debt, with a current ratio of 6.9.

Insiders Are Selling Into the Rally — Worth Watching

Director Jean Francois Formela sold roughly $2.46 million in shares across June 22–24 at prices between $13.95 and $14.61.

CEO Ram Aiyar sold $197,000 in shares over the prior three months with no recorded purchases. While some sales were executed under pre-arranged trading plans , the pattern adds a note of caution against the otherwise bullish backdrop. Investors betting on Korro are fundamentally wagering that early science translates into clinical success — a proposition where history says the odds are long.